Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

9 results about "Ziprasidone" patented technology

Ziprasidone injection is used to treat occurrences of severe agitation in patients with schizophrenia.

Method for detecting impurities of warning structure in ziprasidone

The invention relates to a method for detecting warning structure impurities in ziprasidone. The detection method comprises the step of detecting two warning structure impurities in ziprasidone by using a high performance liquid chromatography-mass spectrometry (LC-MS) and using a methanol-neutral to weakly alkaline buffer salt solution as a flowing phase. According to the detection method, the impurity A higher than 0.38 ppm and the impurity B-ZZ1 higher than 1.77 ppm in ziprasidone can be quantitatively detected, the practicability is high, and the detection process is simple and rapid.
Owner:CHONGQING RUIEN PHARM CO LTD +1

Ziprasidone sustained-release granule, ziprasidone controlled-release tablet and preparation method

The invention relates to the technical field of pharmaceutical preparations, in particular to ziprasidone sustained-release granules, ziprasidone controlled-release tablets and a preparation method. The invention aims to solve the problem of incomplete filling during sustained-release particle tabletting. The first aspect of the invention is to provide a ziprasidone sustained-release particle, and in the ziprasidone sustained-release particle, the proportion of particles with the particle size greater than 250 [mu] m is less than 30% by weight. The second aspect of the invention is to provide a method for preparing the ziprasidone sustained-release granule. The third aspect is to provide a ziprasidone controlled release tablet comprising the ziprasidone sustained release particle. The fourth aspect is to provide a method for preparing the ziprasidone controlled release tablet.
Owner:TAIZHOU OVERSEAS PHARMA LTD

Detection method of intermediate 5-chloroethyl-6-chloroindole-2-ketone for ziprasidone synthesis

The invention provides a detection method of an intermediate 5-chloroethyl-6-chloroindole-2-ketone for ziprasidone synthesis, and belongs to the technical field of drug quality analysis and detection. According to the method, a cyano silane bonded silica gel chromatographic column is selected, acetonitrile in a certain proportion and a phosphate-triethylamine buffer solution with the pH value of 5.0 + / -0.2 are adopted as mobile phases, program gradient elution is cooperatively carried out, a main product can be effectively separated from impurities, and high separation degree and analysis sensitivity are achieved; according to the method, a diode array detector is adopted, and 2008-2022 Shimadzu Corporation LabSolutions software / similar software carried by the diode array detector is used for confirming the maximum absorption wavelength and the relative percentage content of main impurities in the main product 5-chloroethyl-6-chloroindole-2-ketone. The method provided by the invention is short in analysis time, simple in analysis operation, capable of determining whether the main product contains impurities or not, and relatively good in repeatability and adaptability.
Owner:JIANGXI KAIYUAN BIOMEDICAL TECH CO LTD

Detection method of intermediate 3-(1-piperazinyl)-1, 2-benzisothiazole hydrochloride for ziprasidone synthesis

ActiveCN119064497AReduce post-processing costseasy to separateComponent separationKetone synthesisAssay sensitivity
The invention provides a method for detecting an intermediate 3-(1-piperazinyl)-1, 2-benzisothiazole hydrochloride for ziprasidone synthesis, and belongs to the technical field of drug quality analysis and detection.The method comprises the steps that acetonitrile and a triethylamine-containing aqueous solution in a certain proportion are selected as mobile phases, program gradient elution is cooperatively carried out, and the separation degree and analysis sensitivity are improved; according to the method, a diode array detector is adopted, 2008-2022 Shimadzu Corporation LabSolutions software / similar software carried by the diode array detector is used for confirming the relative quantification of the main impurities in the main product 3-(1-piperazinyl)-1, 2-benzisothiazole hydrochloride, and the method provided by the invention is short in analysis time, simple in analysis operation and relatively good in repeatability and adaptability.
Owner:JIANGXI KAIYUAN BIOMEDICAL TECH CO LTD

Detection method of ziprasidone synthesis intermediate 3-(1-piperazine)-1,2-benzisothiazole hydrochloride

ActiveCN119064497BReduce post-processing costseasy to separateKetone synthesisAssay sensitivity
The invention provides a detection method for ziprasidone synthesis intermediate 3-(1-piperazinyl)-1,2-benzisothiazole hydrochloride, belonging to the technical field of drug quality analysis and detection. The invention selects acetonitrile and triethylamine-containing aqueous solution in a certain proportion as mobile phases, performs programmed gradient elution in coordination, and improves separation degree and analytical sensitivity; a diode array detector is adopted, and the 2008-2022Shimadzu Corporation LabSolutions software / similar software carried by the diode array detector is used to confirm the relative quantification of main impurities in the main product 3-(1-piperazinyl)-1,2-benzisothiazole hydrochloride; and the method provided by the invention has short analysis time, simple analysis operation and good repeatability and adaptability.
Owner:JIANGXI KAIYUAN BIOMEDICAL TECH CO LTD

Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia

A combination for use in the prevention, alleviation or treatment of schizophrenia, comprising (a) a carbamate compound of the following Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof; and (b) an atypical antipsychotic agent selected from the group consisting of asenapine, clozapine, iloperidone, olanzapine, lurasidone, paliperidone, quetiapine, risperidone and ziprasidone: wherein, R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 thioalkoxy and C1-C8 alkoxy; and one of A1 and A2 is CH, and the other is N.
Owner:SK BIOPHARMACEUTICALS CO LTD

Ziprasidone formulations

Provided is an aqueous formulation of ziprasidone, stored for up to six months at 40° C., suitable for intramuscular injection. In these embodiments, the aqueous formulation (a) provides greater than 98% purity of the ziprasidone and / or (b) has less than 0.5% of USP Related Compound C with respect to ziprasidone. Also provided is a method of administering ziprasidone to a patient, the method comprising administering the above formulation to the patient intramuscularly through a syringe.
Owner:BELOTECA INC

Ziprasidone starting material related substance detection method

The invention relates to a method for detecting related substances of a ziprasidone starting material. The starting material is 6-chloroindole-2-ketone; according to the detection method, high performance liquid chromatography is adopted, phenylsilane bonded silica gel or adamantyl bonded silica gel is used as a chromatographic column of a filler, mobile phases comprise a mobile phase A and a mobile phase B, the mobile phase A is a monopotassium phosphate aqueous solution, the mobile phase B is methanol, and the 6-chloroindole-2-one related substances are detected. The method is good in specificity, high in sensitivity, high in accuracy and good in repeatability.
Owner:NANJING CHIA TAI TIANQING PHARMA